Amgen Inc - Company Profile
Powered by 
All the sales intelligence you need on Amgen Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Amgen Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Amgen Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
View moreAmgen Inc (Amgen) is a biotechnology company that focuses on discovering, developing, manufacturing, and delivering innovative medicines. The company's products focus on the therapy areas such as cancer, heart disease, osteoporosis, inflammatory diseases, and rare diseases. Amgen offers its products across pharmaceutical wholesale distributors and directly to consumer channels, including healthcare providers, including physicians, clinics, hospitals, and pharmacies, through brands Actimmune, Blincyto, Epogen, Kanjinti, Mvas, Parsabiv, and Tepezza, among others, in Asia Pacific, the Americas, Europe, the Middle East and Africa. It operates manufacturing facilities in the US, Puerto Rico, Ireland, the Netherlands, and Singapore. Amgen is headquartered in Thousand Oaks, California, the US.
Headquarters
United States of America
Address
One Amgen Center Drive, Thousand Oaks, California, 91320-1799
Website
www.amgen.com
Telephone
1 805 4471000
No of Employees
31,500
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
AMGN (NASD)
Revenue (2024)
$36.8B
10%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
88.5%
(2024 vs 2023)
Market Cap*
$201.9B
Net Profit Margin (2024)
XYZ
71.4%
(2024 vs 2023)
* As of and is in US$
Amgen Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Erenumab-Aooe | Actimmune |
| Interferon Gamma-1b | Amjevita |
| Adalimumab-Atto | Aranesp |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In June, the company secured marketing authorization for IMDYLLTRA (tarlatamab) as a monotherapy to treat adult patients with extensive-stage small cell lung cancer (ES-SCLC). |
| 2026 | Regulatory Approval | In February, the company won approval from the European Commission for Uplizna (inebilizumab) as an add-on treatment to standard therapy for adults with generalised myasthenia gravis. |
| 2026 | Acquisitions/Mergers/Takeovers | In January, the company acquired Dark Blue Therapeutics for US$840 million. |
Competitor Comparison
| Key Parameters | Amgen Inc | Eli Lilly and Co | Merck & Co Inc | Pfizer Inc | AbbVie Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Thousand Oaks | Indianapolis | Rahway | New York City | North Chicago |
| State/Province | California | Indiana | New Jersey | New York | Illinois |
| No. of Employees | 31,500 | 50,605 | 75,000 | 75,000 | 57,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Robert A. Bradway | Chairman; Chief Executive Officer | Executive Board | 2013 | 63 |
| Peter H. Griffith | Chief Financial Officer; Executive Vice President | Senior Management | 2020 | 67 |
| Scott Skellenger | Chief Information Officer; Senior Vice President | Senior Management | 2024 | - |
| Sean Bruich | Chief Technology Officer; Senior Vice President | Senior Management | 2026 | - |
| Nancy A. Grygiel | Senior Vice President - Worldwide Compliance and Business Ethics; Chief Compliance Officer | Senior Management | 2020 | 58 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer